301 related articles for article (PubMed ID: 29483236)
1. Penetrance estimates for
Evans DG; Woodward E; Harkness EF; Howell A; Plaskocinska I; Maher ER; Tischkowitz MD; Lalloo F
J Med Genet; 2018 Jul; 55(7):442-448. PubMed ID: 29483236
[TBL] [Abstract][Full Text] [Related]
2. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
[TBL] [Abstract][Full Text] [Related]
3. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
[TBL] [Abstract][Full Text] [Related]
4. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
5. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
6. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
7. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
8. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER
BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387
[TBL] [Abstract][Full Text] [Related]
9. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
14. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
15. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Mavaddat N; Peock S; Frost D; Ellis S; Platte R; Fineberg E; Evans DG; Izatt L; Eeles RA; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Douglas F; Hodgson S; Walker L; Porteous ME; Morrison PJ; Side LE; Kennedy MJ; Houghton C; Donaldson A; Rogers MT; Dorkins H; Miedzybrodzka Z; Gregory H; Eason J; Barwell J; McCann E; Murray A; Antoniou AC; Easton DF;
J Natl Cancer Inst; 2013 Jun; 105(11):812-22. PubMed ID: 23628597
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
17. Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm.
Morris B; Hughes E; Rosenthal E; Gutin A; Bowles KR
BMC Genet; 2016 Jul; 17(1):99. PubMed ID: 27363726
[TBL] [Abstract][Full Text] [Related]
18. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract][Full Text] [Related]
19. Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers.
South SA; Vance H; Farrell C; DiCioccio RA; Fahey C; Piver MS; Rodabaugh KJ
Cancer; 2009 Jan; 115(2):324-33. PubMed ID: 19117025
[TBL] [Abstract][Full Text] [Related]
20. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
